PhIII dealmaking frenzy in i/o continues as AstraZeneca follows PACIFIC with a new Incyte IDO1 combo
Incyte CEO Hervé Hoppenot made it clear a long time ago that he was happily fast and loose about which approved PD-(L)1 drug he partnered …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
